Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Trading 03-23 13:20:54 EDT

4.78

-0.04

-0.83%

High4.94	Low4.73	Vol189.23K
Open4.91	D1 Closing4.82	Amplitude4.36%
Mkt Cap155.45M	Tradable Cap108.15M	Total Shares32.52M
T/O912.89K	T/O Rate0.84%	Tradable Shares22.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":4.78,"timestamp":1774286449370,"preClose":4.82,"halted":0,"volume":189234,"delay":0,"changeRate":-0.008298755186721999,"floatShares":22626486,"shares":32521599,"eps":-1.58,"marketStatus":"Trading","change":-0.04,"latestTime":"03-23 13:20:54 EDT","open":4.91,"high":4.94,"low":4.73,"amount":912894.8474358,"amplitude":0.043568,"askPrice":4.8,"askSize":510,"bidPrice":4.76,"bidSize":510,"shortable":3,"etf":0,"ttmEps":-1.58,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":4.82,"preHourTrading":{"tag":"盘前","latestPrice":5,"preClose":4.82,"latestTime":"08:00 EDT","volume":112,"amount":544.499984,"timestamp":1774267217642,"change":0.18,"changeRate":0.037344,"amplitude":0.03112},"postHourTrading":{"tag":"盘后","latestPrice":4.92,"preClose":4.82,"latestTime":"18:46 EDT","volume":7570,"amount":36527.22,"timestamp":1774046773947,"change":0.1,"changeRate":0.020747,"amplitude":0.020747},"volumeRatio":1.026895,"impliedVol":1.8157,"impliedVolPercentile":0.8526},"requestUrl":"/m/hq/s/SGMT","defaultTab":"news","newsList":[{"id":"2619193646","title":"Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619193646?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:50","pubTimestamp":1773395409,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Korro Bio (KRRO – Research Report), Sagimet Biosci...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-korro-bio-krro-sagimet-biosciences-inc-class-a-sgmt-and-bristol-myers-squibb-bmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-korro-bio-krro-sagimet-biosciences-inc-class-a-sgmt-and-bristol-myers-squibb-bmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","LU1093756325.SGD","LU0321505439.SGD","LU0225284248.USD","LU0868494617.USD","IE00BJJMRZ35.SGD","LU0882574055.USD","XLV","LU2133065610.SGD","LU0237698245.USD","BK4559","LU1868836591.USD","LU1868836757.USD","LABU","LU2360032135.SGD","LU1670711123.USD","BMY","LU1883839398.USD","BK4588","KRRO","LU1093756168.USD","XBI","LU0456855351.SGD","LU0306807586.USD","LU1291159041.SGD","LU1868837136.USD","SGMT","BK4137","BK4585","BK4581","LU0096364046.USD","LU1323610961.USD","LU1670710661.SGD","LU1718418525.SGD","IE00B2B36J28.USD","LU0306806265.USD","LU1989771016.USD","HCSG","LU2242652126.USD","IE00BFXG1179.USD","LU1571399168.USD","LU0029874061.USD","LU0061475181.USD","LU0128526141.USD","LU1074936037.SGD","LU1430594728.SGD","LU1032466523.USD","LU1868836914.USD","BK4007","LU1585245621.USD"],"gpt_icon":0},{"id":"2618372541","title":"Sagimet Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618372541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618372541?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:31","pubTimestamp":1773322272,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc reports results for the quarter ended December 31 - Earnings SummarySagimet Biosciences Inc SGMT.OQ reported a quarterly adjusted loss of 29 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL8N4001NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2618279922","title":"Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618279922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618279922?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:38","pubTimestamp":1773250680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 13:38 ET (17:38 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2618929895","title":"Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618929895","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618929895?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:15","pubTimestamp":1773242133,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-undervalued-mash-and-acne-pipeline-with-best-in-class-combination-potential-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-undervalued-mash-and-acne-pipeline-with-best-in-class-combination-potential-supports-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","SGMT","BK4588","BK4585","BK4139","XLV","XBI","LABU"],"gpt_icon":0},{"id":"2618299944","title":"Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2618299944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618299944?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:59","pubTimestamp":1773230348,"startTime":"0","endTime":"0","summary":"An update from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now available. Sagimet Biosciences reported its fourth-quarter and full-year 2025 r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-reports-2025-results-highlights-clinical-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-biosciences-reports-2025-results-highlights-clinical-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","PRGS","LU2065732104.USD","SGMT","BK4139"],"gpt_icon":0},{"id":"2618941265","title":"Sagimet Biosciences Q4 net loss narrows as R&D expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941265?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:39","pubTimestamp":1773229167,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Q4 net loss narrows as R&D expenses fallOverviewU.S. biopharma firm's Q4 net loss narrowed yr/yrQ4 research and development expense declined from prior yearCompany completed Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL1N3ZZ0JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2618412839","title":"Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618412839","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618412839?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:36","pubTimestamp":1773228970,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.48) by 39.08 percent. This is a 42 percent increase over losses of $(0.50) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51182417/sagimet-biosciences-q4-eps-0-29-beats-0-48-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2618941117","title":"Sagimet Biosciences Q4 net loss narrows 41% to USD 9.57 million, cash falls 29% to USD 113.12 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941117","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941117?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:31","pubTimestamp":1773228684,"startTime":"0","endTime":"0","summary":"Sagimet reported a Q4 net loss of USD 9.57 million, narrowing 41% from the prior-year period. Q4 R&D expense was USD 6.73 million, down 53%. For FY 2025, net loss was USD 51.04 million, widening 12%, while R&D expense was USD 39.05 million. Cash, cash equivalents and marketable securities totaled USD 113.12 million at year-end, down 29%. The company said it completed a Phase 1 pharmacokinetic trial of denifanstat in combination with resmetirom and plans to initiate a Phase 2 proof-of-concept trial in F4 MASH in 2H 2026, and it is running a first-in-human Phase 1 trial of FASN inhibitor TVB-3567.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLblFtcD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","SG9999014013.SGD","LU0314104364.USD","BK4139","LU2210149790.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","SGMT","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2618455941","title":"Sagimet Biosciences Q4 EPS USD -0.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2618455941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618455941?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:30","pubTimestamp":1773228601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nPLX931C0A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2618941435","title":"Press Release: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941435?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:30","pubTimestamp":1773228600,"startTime":"0","endTime":"0","summary":"Completed Phase 1 pharmacokinetic  clinical trial of denifanstat and resmetirom combination. Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredients . First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing. Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis. \"2025 saw important advances in both our MASH and acne programs,\" said David Happel, Chief Executive Officer of Sagimet. \"We completed our Phase 1 PK clinical trial of denifanstat and resmetirom combination and anticipate advancing the combination into a proof-of-concept Phase 2 clinical trial in F4 MASH, for which there are currently no approved treatments, in the second half of the year. In acne, positive 52-week data from our license partner Ascletis' Phase 3 open-label acne trial with denifanstat will support Ascletis' NDA that was accepted","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","API","BK4535","BK4551","BK4085","SGMT","R","BK4022","BK4232","00511","BK4139","BK1145","BK4023","BK4503","DDI","BK4218"],"gpt_icon":0},{"id":"2618587259","title":"Sagimet Biosciences Inc  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618587259","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618587259?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:53","pubTimestamp":1773147187,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc  expected to post a loss of41cents a share - Earnings Preview Sagimet Biosciences Inc SGMT.OQ SGMT.O is expected to  show no change in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL8N3ZY1A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2614841080","title":"Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2614841080","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614841080?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:00","pubTimestamp":1772020800,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Feb.  25, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244457/0/en/Sagimet-Biosciences-Announces-Participation-in-Three-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2611889221","title":"Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2611889221","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611889221?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:05","pubTimestamp":1770948306,"startTime":"0","endTime":"0","summary":"New insider activity at Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has taken place on February 12, 2026. Sagimet Biosciences, Inc. Class A has s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-sagimet-executives-quietly-unload-shares-in-coordinated-insider-move-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-sagimet-executives-quietly-unload-shares-in-coordinated-insider-move-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2609374299","title":"Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374299","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374299?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292843,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. wird am 11. Februar 2026 am Guggenheim Emerging Outlook: Biotech Summit in New York teilnehmen und am 26. Februar 2026 beim Oppenheimer 36th Annual Healthcare Life Sciences Conference vertreten sein.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2BfTWH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4588","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","SGMT","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2608807643","title":"After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807643","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608807643?lang=en_us&edition=fundamental","pubTime":"2026-02-04 04:27","pubTimestamp":1770150420,"startTime":"0","endTime":"0","summary":"Shares of Sagimet Biosciences were up as much as 12% Tuesday morning, on encouraging clinical trial results for its acne treatment and a new Buy recommendation from Guggenheim Securities.For much of its history, the San Mateo, Calif-based firm played up the promise of its novel drug for treating liver diseases brought on by obesity. But lately, it is drawing attention for those drugs' success at clearing a more familiar affliction: acne.The news helped lift Sagimet stock Tuesday to $7.20 and bring the little company's market cap to $230 million. That is well below the $16 level where Sagimet came public in 2023. But in a Tuesday note launching coverage on the company, Guggenheim's Seamus Fernandez says the stock can rise as high as $27, if either the liver or acne drug reach his expectations.If approved and launched by 2030, he thinks the drug's sales as a first line treatment for acne could surpass a billion dollars. The existing treatments include generic versions of the Roche drug A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK1161","01672","BK1515","BK1574","BK4139"],"gpt_icon":0},{"id":"1119251824","title":"Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded","url":"https://stock-news.laohu8.com/highlight/detail?id=1119251824","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119251824?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:54","pubTimestamp":1770130488,"startTime":"0","endTime":"0","summary":"Here is a summary of the latest analyst ratings from Wall Street that are most closely watched and have significant market impact. The following are today's key rating changes compiled by The Fly...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU1674673691.USD","LU0198837287.USD","SG9999000418.SGD","LU0348723411.USD","LU2089284900.SGD","IE00BQXX3C00.GBP","DIS","BK4534","BK4588","LU0868494708.USD","IE00BFXG0V08.USD","LU1548497426.USD","ADBE","LU0792757196.USD","LU1720051108.HKD","LU2236285917.USD","LU0345774391.USD","V","LU1084165304.USD","LU0157215616.USD","LU1366333091.USD","LU2089283258.USD","BK4585","LU0006306889.USD","LU0081259029.USD","LU0861579265.USD","LU1691799644.USD","BK4533","LU0057025933.USD","BK4543","LU0672654240.SGD","IE00B5TLWC47.USD","BK4592","LU0957791311.USD","LU0109391861.USD","LU1235294995.USD","AFRM","LU0234570918.USD","LU2125154935.USD","LU1623119135.USD","TASK","LU0889566641.SGD","LU0109392836.USD","QTWO","ELV","JBLU","LU0082616367.USD","LU0234572021.USD","XOM","LU1046421795.USD","BK4566","LU0708995401.HKD","CTRA","LU0965509101.SGD","LU2317271919.USD","LU0170899867.USD","BK4528","LU0345774631.USD","LU1674673428.USD","LU2210150020.SGD","LU2360032135.SGD","BK4527","SGMT","LU0320765059.SGD","STAA","LU2210149790.SGD","LU0965509283.SGD","IE00B19Z9505.USD","BK4023","IE00BQXX3D17.EUR","LU0069063385.USD","LU2357305700.SGD","LU0289961442.SGD","SGXZ51526630.SGD","BK4554","LU0061474960.USD","LU1712237335.SGD","MA","LU1720051017.SGD","LU1119994496.HKD","LU0868494617.USD","SG9999001424.SGD","LU1823568750.SGD","LU0511384066.AUD","AKTS","LU2237438978.USD","LU0719512351.SGD","LU0342679015.USD","LU1633808545.USD","LU2458330243.SGD","LU1261432733.SGD","LU2458330169.SGD","LU1267930813.SGD","IE0009356076.USD","LU2125154778.USD","LU1803068979.SGD","LU0289739343.SGD","LU0889565833.HKD","BK4567","LU0158827948.USD","LU0557290698.USD","FIGR","LU0472753341.HKD","BK4581","LU1815333072.USD","IE00BQXX3F31.USD","LU0106261372.USD","IE00BYQQ9H92.USD","LU2023251221.USD","LU2095319765.USD","SGXZ99366536.SGD","LU1267930730.SGD","PLTR","LU0942090050.USD","SGXZ81514606.USD","LU0314104364.USD","LU0965509010.AUD"],"gpt_icon":1},{"id":"2608876857","title":"Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608876857?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:39","pubTimestamp":1770122340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 07:39 ET (12:39 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2608759688","title":"Sagimet Biosciences initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2608759688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608759688?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:21","pubTimestamp":1770121267,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $27 price target The firm believes the c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2608482288","title":"Sagimet Biosciences price target raised to $37 from $29 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2608482288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608482288?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:20","pubTimestamp":1770114010,"startTime":"0","endTime":"0","summary":"Clear Street raised the firm’s price target on Sagimet Biosciences (SGMT) to $37 from $29 and keeps a Buy rating on the shares. The firm says the 5...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-37-from-29-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-37-from-29-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2608982333","title":"Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608982333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608982333?lang=en_us&edition=fundamental","pubTime":"2026-02-03 15:51","pubTimestamp":1770105066,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sagimet Biosciences, Inc. Class A (SGMT – Research...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-sagimet-biosciences-inc-class-a-sgmt-and-siemens-healthineers-ag-othersemhf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-sagimet-biosciences-inc-class-a-sgmt-and-siemens-healthineers-ag-othersemhf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XBI","LABU","BK4581","BK4210","AG","BK4137","SGMT","HCSG","BK4139","XLV","BK4585","BK4588","LU0128526141.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":-0.0749},{"period":"1month","weight":-0.0819},{"period":"3month","weight":-0.2325},{"period":"6month","weight":-0.2607},{"period":"1year","weight":0.1901},{"period":"ytd","weight":-0.1858}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction